Ira A Blaufarb, MD
- ASSOCIATE PROFESSOR | Medicine, Cardiology
Dr. Blaufarb is a passionate and gentle physician with a particular interest in women’s cardiac health. His patients love his ability to translate complex cardiac conditions into understandable terms as well as his natural gift to encourage and comfort. Dr. Blaufarb is an avid cyclist with a keen business sense evidenced by his recent completion of the NYU Stern Executive MBA program.
Dr. Blaufarb received his Bachelor of Science from Union College and his Doctor of Medicine from Jefferson Medical College. He completed his residency at Mt. Sinai Hospital in New York, and a fellowship in cardiology at the Albert Einstein College of Medicine. From 1995 to 1996, and Dr. Blaufarb was the Administrative Chief Fellow in the Division of Cardiology at Albert Einstein College of Medicine. Dr Blaufarb is board certified in Cardiovascular Disease and Nuclear Cardiology. In addition to acting as an Associate Professor at Mount Sinai, Dr. Blaufarb is also on staff at Lenox Hill Hospital.
- Cardiovascular Disease
- Nuclear Cardiology
MD, Jefferson Medical College
MBA, NYU Stern School of Business
Cardiology Fellowship, Albert Einstein College of Medicine
Medical Internship, The Mount Sinai Hospital
Residency, Internal Medicine, Mount Sinai Hospital
Fellowship, Cardiology, Montefiore Medical Center
Blaufarb I, Pfeifer TM, Frishman WH. beta-blockers. Drug interactions of clinical significance. Drug safety : an international journal of medical toxicology and drug experience 1995 Dec; 13(6).
Blaufarb IS, Sonnenblick EH. The renin-angiotensin system in left ventricular remodeling. The American journal of cardiology 1996 May; 77(13).
Hamroff G, Blaufarb I, Mancini D, Katz SD, Bijou R, Jondeau G, Olivari MT, Thomas S, LeJemtel TH. Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure. Journal of cardiovascular pharmacology 1997 Oct; 30(4).
Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari MT, Thomas S, Le Jemtel TH. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999 Mar; 99(8).
Frishman W, Sonnenblick E. Antiplatelet and Anticoagulant Therapy in Cardiovascular Disease. In: Cardiovascular Pharmacotherapeutics. McGraw-Hill;.